<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250501065557N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-05-20</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Pillar Pain After Carpal Tunnel Release</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Skin Closure Techniques in Carpal Tunnel Release: A Randomized Controlled Trial Assessing Postoperative Pillar Pain and Scar Quality</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>128</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83262</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This study possesses several unique design features. First, a double-blinded assessment protocol was employed: patients were unaware of their group allocation, and the postoperative outcome assessor was blinded to group assignment and remained completely independent of the surgical team. Second, the study utilized a culturally adapted and psychometrically validated Persian version of the Patient and Observer Scar Assessment Scale (POSAS), ensuring reliable and standardized scar evaluation for the target population. Third, all surgical procedures were performed by a single fellowship-trained hand surgeon, which minimized variability in surgical technique. Fourth, the study compared two distinct yet commonly used skin closure methods—subcuticular absorbable Monocryl sutures and interrupted non-absorbable Nylon sutures—allowing for a meaningful evaluation of the impact of suture type on postoperative outcomes, Randomization description: In this study, block randomization with variable block sizes (4, 6, and 8) will be performed using a computer-generated random sequence. This method is designed to ensure balanced allocation of participants across the two groups while minimizing the predictability of the assignment sequence.

The unit of randomization is the individual, and each participant will be independently assigned to one of the two study groups.

To cover the total sample size of 128 participants, a total of 23 blocks will be used, consisting of 11 blocks of size 4, 6 blocks of size 6, and 6 blocks of size 8. Within each block, participants will be allocated equally and randomly to the two groups.

The randomization sequence will be generated using R statistical software by an independent research coordinator who is not involved in patient recruitment or outcome assessment.

To ensure allocation concealment, sequentially numbered, sealed, opaque envelopes will be used. Each envelope will be opened by the investigator only after the patient meets the eligibility criteria and is formally enrolled in the study. This procedure is intended to prevent allocation bias and to preserve the internal validity of the trial, Blinding description: All postoperative assessments were performed by a single trained evaluator who was independent of the surgical team and had no involvement in any part of the surgical procedure. The evaluator was unaware of group allocation at the time of patient enrollment, and the patients were also blinded to their assigned group. Thus, the study was conducted in a double-blinded manner to minimize assessment and performance bias.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pillar pain after carpal tunnel release.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, skin closure will be performed using continuous subcuticular suturing with 4-0 absorbable Monocryl following open carpal tunnel release. This technique involves placing the suture beneath the skin surface, eliminating the need for removal during follow-up. All procedures in this group will be carried out under standardized conditions by a fellowship-trained hand surgeon, following the same postoperative care protocol as the control group. Intervention 2: Control group: In the control group, skin closure will be performed using non-absorbable 4-0 Nylon sutures applied with an interrupted vertical mattress technique following open carpal tunnel release. These sutures will be removed at the first postoperative visit. All surgeries in this group will also be performed under standardized conditions by a fellowship-trained hand surgeon, following the same postoperative care protocol as the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to ethical considerations, concerns about participant confidentiality, and the lack of an established secure data-sharing infrastructure, there is currently no plan to share individual participant data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Naghizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Forsat Shirazi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419933813</zip>
        <telephone>+98 21 6612 0457</telephone>
        <email>hamednaghizadeh@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamed Naghizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Forsat Shirazi</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419933813</zip>
        <telephone>+98 21 6612 0457</telephone>
        <email>hamednaghizadeh@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years old scheduled for carpal tunnel surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients under 18 years of age
Pregnant individuals
Unable to provide reliable postoperative feedback due to cognitive or communication limitations
Patients scheduled for concurrent procedures such as trigger finger or cubital tunnel release
Individuals who declined to participate
Those whose surgeries were canceled or not scheduled
Patients excluded due to enrollment or protocol deviations</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, skin closure will be performed using continuous subcuticular suturing with 4-0 absorbable Monocryl following open carpal tunnel release. This technique involves placing the suture beneath the skin surface, eliminating the need for removal during follow-up. All procedures in this group will be carried out under standardized conditions by a fellowship-trained hand surgeon, following the same postoperative care protocol as the control group.</i_keyword>
      <i_keyword>Control group: In the control group, skin closure will be performed using non-absorbable 4-0 Nylon sutures applied with an interrupted vertical mattress technique following open carpal tunnel release. These sutures will be removed at the first postoperative visit. All surgeries in this group will also be performed under standardized conditions by a fellowship-trained hand surgeon, following the same postoperative care protocol as the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pillar pain, defined as pain in the thenar and hypothenar regions following open carpal tunnel release, will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). Scar quality will be evaluated using the Patient and Observer Scar Assessment Scale (POSAS), which includes two components. The Patient Scale consists of six items—pain, itching, color, stiffness, thickness, and irregularity—each scored from 1 (similar to normal skin) to 10 (worst condition). The Observer Scale also includes six items—vascularity, pigmentation, thickness, relief, pliability, and surface area—scored on the same scale. Higher total scores in both scales indicate poorer scar quality. Timepoint: 2 weeks postoperatively - 6 weeks postoperatively - 3 months (12 weeks) postoperatively. Method of measurement: Pillar pain, defined as pain in the thenar and hypothenar regions following open carpal tunnel release, will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). Scar quality will be evaluated using the Patient and Observer Scar Assessment Scale (POSAS), which includes two components. The Patient Scale consists of six items—pain, itching, color, stiffness, thickness, and irregularity—each scored from 1 (similar to normal skin) to 10 (worst condition). The Observer Scale also includes six items—vascularity, pigmentation, thickness, relief, pliability, and surface area—scored on the same scale. Higher total scores in both scales indicate poorer scar quality.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-12-04</approval_date>
        <contact_name>Ethics committee of TEHRAN University of Medical Sciences</contact_name>
        <contact_address>Forsat Shirazi Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
